Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Debt / DBCV 1.500%11/1
-
Market price (% of par)
-
229.75%
-
Total 13F principal
-
$509,419,000
-
Principal change
-
-$10,290,000
-
Total reported market value
-
$1,173,397,315
-
Number of holders
-
45
-
Value change
-
+$4,020,127
-
Number of buys
-
19
-
Number of sells
-
19
Institutional Holders of SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 as of Q2 2020
As of 30 Jun 2020,
SAREPTA THERAPEUTICS INC - DBCV 1.500%11/1 was held by
45 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$509,419,000
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, DeepCurrents Investment Group LLC, Allianz Asset Management GmbH, Linden Advisors LP, CALAMOS ADVISORS LLC, D. E. Shaw & Co., Inc., BANK OF AMERICA CORP /DE/, LORD, ABBETT & CO. LLC, and FRANKLIN RESOURCES INC.
This page lists
45
institutional bondholders reporting positions
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.